Nanoliposomes as nonviral vectors in cancer gene therapy
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
John Wiley and Sons Inc
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off-targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions. © 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
Açıklama
Anahtar Kelimeler
CRISPR/Cas9, Liposome, Nonviral Vector, ShRNA, SiRNA
Kaynak
MedComm
WoS Q Değeri
Q1
Scopus Q Değeri
Q2
Cilt
5
Sayı
7
Künye
Yildiz, S. N., Entezari, M., Paskeh, M. D. A., Mirzaei, S., Kalbasi, A., Zabolian, A., ... & Ertas, Y. N. (2024). Nanoliposomes as nonviral vectors in cancer gene therapy. MedComm, 5(7), e583.
